scholarly journals Cripto-1 as a novel therapeutic target for triple negative breast cancer

Oncotarget ◽  
2014 ◽  
Vol 6 (14) ◽  
pp. 11910-11929 ◽  
Author(s):  
Nadia P. Castro ◽  
Natalie D. Fedorova-Abrams ◽  
Anand S. Merchant ◽  
Maria Cristina Rangel ◽  
Tadahiro Nagaoka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Therapeutic Target ◽  
Triple Negative ◽  
Novel Therapeutic

scholarly journals CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer

Cancers ◽  
2018 ◽  
Vol 10 (12) ◽  
pp. 525 ◽  
Author(s):  
Alexander Ring ◽  
Cu Nguyen ◽  
Goar Smbatyan ◽  
Debu Tripathy ◽  
Min Yu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Drug Resistance ◽  
Triple Negative Breast Cancer ◽  
Therapeutic Target ◽  
Triple Negative ◽  
Creb Binding Protein ◽  
Novel Therapeutic

Background: Triple negative breast cancers (TNBCs) are an aggressive BC subtype, characterized by high rates of drug resistance and a high proportion of cancer stem cells (CSC). CSCs are thought to be responsible for tumor initiation and drug resistance. cAMP-response element-binding (CREB) binding protein (CREBBP or CBP) has been implicated in CSC biology and may provide a novel therapeutic target in TNBC. Methods: RNA Seq pre- and post treatment with the CBP-binding small molecule ICG-001 was used to characterize CBP-driven gene expression in TNBC cells. In vitro and in vivo TNBC models were used to determine the therapeutic effect of CBP inhibition via ICG-001. Tissue microarrays (TMAs) were used to investigate the potential of CBP and associated proteins as biomarkers in TNBC. Results: The CBP/ß-catenin/FOXM1 transcriptional complex drives gene expression in TNBC and is associated with increased CSC numbers, drug resistance and poor survival outcome. Targeting of CBP/β-catenin/FOXM1 with ICG-001 eliminated CSCs and sensitized TNBC tumors to chemotherapy. Immunohistochemistry of TMAs demonstrated a significant correlation between FOXM1 expression and TNBC subtype. Conclusion: CBP/β-catenin/FOXM1 transcriptional activity plays an important role in TNBC drug resistance and CSC phenotype. CBP/β-catenin/FOXM1 provides a molecular target for precision therapy in triple negative breast cancer and could form a rationale for potential clinical trials.

scholarly journals CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Meiou Dai ◽  
Chenjing Zhang ◽  
Ayad Ali ◽  
Xinyuan Hong ◽  
Jun Tian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Therapeutic Target ◽  
Triple Negative ◽  
Cancer Stemness ◽  
Novel Therapeutic

scholarly journals The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer

Oncotarget ◽  
2016 ◽  
Vol 8 (2) ◽  
pp. 2971-2983 ◽  
Author(s):  
Xinyan Wu ◽  
Muhammad Saddiq Zahari ◽  
Santosh Renuse ◽  
Dhanashree S. Kelkar ◽  
Mustafa A. Barbhuiya ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Triple Negative Breast Cancer ◽  
Receptor Tyrosine Kinase ◽  
Therapeutic Target ◽  
Triple Negative ◽  
Novel Therapeutic
Sign in / Sign up

Export Citation Format

Share Document